Geode Capital Management’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Geode Capital Management’s Portfolio ZYBT Stock Details ZYBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-29,068	Closed	-$19.7K	–	4544
2026 Q2	$19.7K	Hold	29,068	–	–	﹤0.01%	4376
2026 Q1	$27.2K	Hold	29,068	–	–	﹤0.01%	4424
2025 Q4	$33.4K	Hold	29,068	–	–	﹤0.01%	4309
2025 Q3	$76.2K	Hold	29,068	–	–	﹤0.01%	4196
2025 Q2	$174K	Buy	+29,068	New	+$231K	﹤0.01%	3920

Other funds holding ZYBT

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Geode Capital Management's ZYBT Position: Q3 2026 in Review

Geode Capital Management sold out of Zhengye Biotechnology Holding (ZYBT) in Q3 2026, closing a stake of 29,068 shares — an estimated $19.7K sold.

Geode Capital Management first reported a position in ZYBT in Q2 2025 and held it in 5 quarters. The position peaked at $174K in Q2 2025. 4 funds tracked by Wall St. Rank hold ZYBT as of Q3 2026.

Geode Capital Management reported no remaining Zhengye Biotechnology Holding position as of Q3 2026 after selling out during the quarter.
Geode Capital Management sold 29,068 Zhengye Biotechnology Holding shares in Q3 2026, an estimated $19.7K.
Geode Capital Management first reported a position in Zhengye Biotechnology Holding in Q2 2025 and held it in 5 quarters.
Geode Capital Management's Zhengye Biotechnology Holding position peaked at $174K in Q2 2025.
4 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.